Antiestrogen therapy is active in selected ovarian cancer cases: The use of letrozole in estrogen receptor-positive patients

Clinical Cancer Research

Volumn 13, Issue 12, 2007, Pages 3617-3622

  Smyth, John F ^a   Gourley, Charlie ^a   Walker, Graeme ^a   MacKean, Melanie J ^a   Stevenson, Alan ^a   Williams, Alistair R W ^a   Al Nafussi, Awatif ^a   Rye, Tzyvia ^a   Rye, Ron ^a   Stewart, Moira ^a   McCurdy, Janet ^a   Mano, Max ^b   Reed, Nick ^b   McMahon, Tracey ^b   Vasey, Paul ^b   Gabra, Hani ^a   Langdon, Simon P ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; CA 125 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; LETROZOLE; MARKER; SOMATOMEDIN BINDING PROTEIN 5; TREFOIL FACTOR 1; TREFOIL PEPTIDE; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; ENDOCRINE DISEASE; FATIGUE; FEMALE; HEADACHE; HOT FLUSH; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MYALGIA; NAUSEA; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOLOGY; RELAPSE; REMISSION; SOLID TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CA-125 ANTIGEN; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NITRILES; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 34250708027     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2878     Document Type: Article

References (35)

1. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
3. Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide inwomenwith advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
4. Hatch KD, Beecham JB, Blessing JA, et al. Responsiveness of patients with advanced ovarian cancer to tamoxifen. Cancer 1991;68:269-71.
5. Langdon SP, Hawkes MM, Lawrie SS, et al. Oestrogen receptor expression and the effects of estrogen and tamoxifen on the growth of human ovarian carcinoma cell lines. Br J Cancer 1990;62:213-6.
6. Langdon SP, Ritchie A, Young K, et al. Contrasting effects of 17β-estradiol on the growth of human ovarian carcinoma cells in vitro and in vivo. Int J Cancer 1993;55:459-64.
7. Langdon SP, Hirst GL, Miller EP, et al. The regulation of growth and protein expression by estrogen in vitro: a study of 8 human ovarian carcinoma cell lines. J Steroid Biochem Mol Biol 1994;50:131-5.
8. Langdon SP, Rabiasz GJ, Hirst GL, et al. Expression of the heat shock protein HSP27 in human ovarian cancer. Clin Cancer Res 1995;1:1603-9.
9. Walker G, Langdon SP, MacLeod K, et al. Identification of estrogen-regulated biomarkers in ovarian cancer patients treated with letrozole, American Association for Cancer Research Annual Conference. Proc Amer Assoc Cancer Res 2006;47:2323.
10. Dowsett M, Jones A, Johnston SR, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-5.
11. Bowman A, Gabra H, Langdon SP, et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin Cancer Res 2002;8:2233-9.
12. Rustin GJ, Nelstrop AE, Tuxen MK, et al. Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study. Ann Oncol 1996;7:361-4.
13. Rustin GJ, Marples M, Nelstrop AE, et al. Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 2001;19:4054-7.
14. Langdon SP, Crew AJ, Ritchie AA, et al. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur J Cancer 1994;30A:682-6.
15. Markman M, Webster K, Zanotti K, et al. Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum. Gynecol Oncol 2004;94:404-8.
16. Benedetti Panici P, Greggi S, Amoroso M, et al. A combination of platinum and tamoxifen in advanced ovarian cancer failing platinum-based chemotherapy: results of a phase II study. Int J Gynecol Cancer 2001;11:438-44.
17. Markman M, Webster K, Zanotti K, et al. Use of tamoxifen in asymptomatic patients with recurrent small-volume ovarian cancer. Gynecol Oncol 2004;93:390-3.
18. Van Der Velden J, Gitsch G, Wain GV, et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer 1995;5:301-5.
19. Markman M, Iseminger KA, Hatch KD, et al. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. Gynecol Oncol 1996;62:4-6.
20. Slevin ML, Harvey VJ, Osborne RJ, et al. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol 1986;22:309-12.
21. Shirey DR, Kavanagh JJ, Jr., Gershenson DM, et al. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol 1985;66:575-8.
22. Schwartz PE, Keating G, MacLusky N, et al. Tamoxifen therapy for advanced ovarian cancer. Obstet Gynecol 1982;59:583-8.
23. Williams CJ. Tamoxifen for relapse of ovarian cancer. Cochrane Database Syst Rev:CD001034, 2001.
24. del Carmen MG, Fuller AF, Matulonis U, et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol Oncol 2003;91:596-602.
25. Papadimitriou CA, Markaki S, Siapkaras J, et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004;66:112-7.
26. Dixon JM, Jackson J, Renshaw L, et al. Neoadjuvant tamoxifen and aromatase inhibitors: comparisons and clinical outcomes. J Steroid Biochem Mol Biol 2003;86:295-9.
27. Hawkins RA. How best to express oestrogen receptor active. Eur J Cancer 2000;4:S21-3.
28. Masiakowski P, Breathnack R, Bloch J, et al. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acid Res 1982;10:7895-903.
29. Jakowlew S, Breathnack R, Jeltsch J-M, et al. Sequence of the pS2 mRNA induced by estrogen in the human breast cancer cell line MCF-7. Nucleic Acid Res 1984;12:2861-77.
30. Dati C, Antoniotti S, Taverna D, et al. Inhibition of cerbB-2 oncogene expression by estrogens in human breast cancer cells. Oncogene 1990;5:1001-6.
31. Bates NP, Hurst HC. An intron 1 enhancer element mediates oestrogen-induced suppression of ERBB2 expression. Oncogene 1997;15:473-81.
32. Huynh H, Yang X, Pollak M. A role for insulin-like growth factor binding protein 5 in the anti-proliferative action of the antioestrogen ICI 182780. Cell Growth Differ 1996;7:1501-6.
33. Cattoretti G, Andreola S, Clemente C, et al. Vimentin and p53 expression on epidermal growth factor receptor-positive, oestrogen receptor-negative breast carcinomas. Br J Cancer 1988;57:353-7.
34. Domagala W, Lasota J, Bartkowiak J, et al. Vimentin is preferentially expressed inhuman breast carcinomas with low estrogen receptor and high Ki-67 growth fraction. Am J Pathol 1990;136:219-27.
35. O'Donnell AJ, Macleod KG, Burns DJ, et al. Estrogen receptor-α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr Relat Cancer 2005;12:851-66.